Gupta, Diviya
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Lee, Suzanna
Okamura, Ryosuke http://orcid.org/0000-0001-7352-8621
Lim, Hyo Jeong
Kim, Ki Hwan
Sicklick, Jason K. http://orcid.org/0000-0003-4403-0271
Kato, Shumei
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (Grants P30 CA023100)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA168999 and R21CA192072)
Article History
Received: 7 September 2021
Accepted: 11 February 2022
First Online: 28 March 2022
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests: D.G., S.L., R.O., H.J.L., and K.H.K. have nothing to disclose. R.K. has received research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, and Konica Minolta, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Roche, and NeoMed. She receives speaker fees from Roche, owns stock in IDbyDNA, and has an ownership interest in CureMatch, Inc. J.K.S. receives research funding from Novartis Pharmaceuticals, Amgen Pharmaceuticals, and Foundation Medicine; consultant fees from Grand Rounds, Loxo, and Deciphera; and speaker’s fees from Roche and Deciphera. He also owns stocks in Personalis. S.K. serves as a consultant for Foundation Medicine and receives speaker’s fees from Roche.